News

Public · Published

Prestige Consumer Healthcare 3Q 2026: Revenue $336.31M, EPS $0.53 — 10-Q Summary

Prestige Consumer Healthcare reported second-quarter revenue of $336.31 million, up 22.7% year over year, while net income fell 40.1% and diluted earnings per share declined 38.4% to $0.53. Revenue growth reflected acquisitions, while lower gross margins and higher costs weighed on earnings.

Published:

Updated:

What happened

Prestige Consumer Healthcare reported second-quarter revenue of $336.31 million, up 22.7% year over year, while net income fell 40.1% and diluted earnings per share declined 38.4% to $0.53. Revenue growth reflected acquisitions, while lower gross margins and higher costs weighed on earnings.

Confirmed

Global impact / market context

The results show that acquired sales growth did not translate into higher earnings: lower gross profit per dollar of sales, increased marketing and interest costs, and a higher tax rate reduced profits. Continued supply problems could also limit product availability and constrain revenue if not resolved.

Analyst inference

The article describes acquisition-led growth alongside weaker profitability and operational strain. Investors assessing the business may weigh whether added sales can cover acquisition-related costs and restore profit per sale, while supply remediation and facility improvements could add costs before they support steadier production.

Analyst inference

What to watch

  1. Watch whether revenue growth continues in later results and whether the company reports gains beyond those attributed to the OTC Wellness Business and other acquisitions. Analyst inference
  2. Track gross margin, meaning gross profit as a share of revenue, and whether it improves from 51.3% as facility improvement costs and acquired-inventory charges change. Analyst inference
  3. Follow updates on sterile eye-care shortages and quality-system work; lasting supply disruption could restrict product availability, weigh on sales, and require further remediation spending. Analyst inference

Evidence

  • Original source link unavailable